MAX-40279-01
Sponsors
Maxinovel Pty., Ltd.
Conditions
AMLAcute Myeloid LeukemiaLeukemiaMetastatic Colorectal CancerMyelodysplastic SyndromeRelapsed/Refractory Acute Myeloid LeukemiaSolid Tumor
Phase 1
MAX-40279-01 in Patients With Advanced Solid Tumors
NCT04183764
Start: 2019-11-28End: 2022-12-01Target: 30Updated: 2022-01-19
Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
NCT04187495
Start: 2019-04-16End: 2022-12-01Target: 30Updated: 2022-01-19
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
NCT05061147
Start: 2021-09-16End: 2022-10-31Target: 100Updated: 2021-10-01